

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



09.11

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普生藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9989)

**CHANGE OF JOINT COMPANY SECRETARY AND
AUTHORIZED REPRESENTATIVE
AND
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28
AND 8.17 OF THE LISTING RULES**

The Board announces that (i) Mr. Bu has resigned from his positions as the Joint Company Secretary and an Authorized Representative, with effect from September 18, 2020; (ii) Ms. Tan has been appointed as the Joint Company Secretary and an Authorized Representative, with effect from September 18, 2020; and (iii) the Company has applied to the Stock Exchange and has been granted a waiver by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules.

The board (the “**Board**”) of directors (the “**Directors**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that Mr. Bu Haihua (“**Mr. Bu**”) resigned as (i) the joint company secretary of the Company (the “**Joint Company Secretary**”); and (ii) an authorized representative (the “**Authorized Representative**”) under the Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) with effect from September 18, 2020, in order to pursue other business and work commitments.

Mr. Bu has confirmed that he has no disagreement with the Board and that there is no other matters in relation to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board further announces that Ms. Tan Xuan (“**Ms. Tan**”) has been appointed as the Joint Company Secretary and an Authorized Representative, with effect from September 18, 2020.

The biographical details of Ms. Tan are set out as follows:

Ms. Tan Xuan (談煊), born in 1982, holds a bachelor's degree in economics and a master's degree in finance from Renmin University of China. Ms. Tan has been engaged in capital market industry and company research for a long time, participated in the completion of many mergers and acquisitions, and has rich experience in industry analysis and mergers and acquisitions. Ms. Tan has been the director of the Office of secretary to the Board of the Company since June 2020. From April 2007 to November 2014, Ms. Tan successively worked at Harvest Fund Management Co., Ltd., Economy Reseucoves.ons.nt.,

The biographical details of Ms. Chan are set out as follows:

Ms. Chan Sze Ting (陳詩婷) is the joint company secretary of the Company. Ms. Chan currently serves as a senior manager of corporate services of Tricor Services Limited, a global professional services provider specializing in integrated business, corporate and investor services. Ms. Chan has over 14 years of experience in the corporate secretarial field. She has been providing professional corporate services to multiple Hong Kong listed companies. Ms. Chan is currently the joint company secretary of Sinopec Shanghai Petrochemical Company Limited (a company listed on the Main Board of the Stock Exchange, stock code: 338 and listed on the Shanghai Stock Exchange, stock code: 600688), the company secretary of Sunfonda Group Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 1771), Modern Media Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 72), Century Sage Scientific Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 1450) and Vico International Holdings Limited (a company listed on the Main Board of the Hong Kong Stock Exchange, stock code: 1621). Ms. Chan is a Chartered Secretary, a Chartered Governance Professional and an Associate of both The Hong Kong Institute of Chartered Secretaries and The Chartered Governance Institute in the United Kingdom. Ms. Chan holds a bachelor of laws degree from the University of London.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Bu for his valuable contributions to the Company during his tenure of service and extend its warm welcome to Ms. Tan on her new appointment.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
September 18, 2020

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xuan; the non-executive director of the Company is Mr. Bu Haihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.